1060815-86-2 Usage
General Description
2,4-Dichloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound with the molecular formula C7H5Cl2N3. It is a synthetic heterocyclic compound that is used in the pharmaceutical industry for various biological and medicinal applications. 2,4-Dichloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine has been studied for its potential as an anticancer agent and has shown promising results in inhibiting the growth of certain cancer cells. It is also used in the development of novel drug candidates and has the potential for use in the treatment of various diseases. Its unique structure and properties make it a valuable compound for further research and development in the field of medicine and pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1060815-86-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,0,8,1 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1060815-86:
(9*1)+(8*0)+(7*6)+(6*0)+(5*8)+(4*1)+(3*5)+(2*8)+(1*6)=132
132 % 10 = 2
So 1060815-86-2 is a valid CAS Registry Number.
InChI:InChI=1S/C7H5Cl2N3/c1-3-2-10-6-4(3)5(8)11-7(9)12-6/h2H,1H3,(H,10,11,12)
1060815-86-2Relevant articles and documents
Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents
Gong, Chaochao,Huang, Jian,Liu, Yue,Tan, Hanyi,Zhang, Jiawei,Zhang, Qian
, (2021/07/02)
Focal adhesion kinase (FAK) is a ubiquitous intracellular non-receptor tyrosine kinase, which is involved in multiple cellular functions, including cell adhesion, migration, invasion, survival, and angiogenesis. In this study, a series of 7H-pyrrolo[2,3-d
PROTEIN KINASE INHIBITORS
-
Page/Page column 27-28, (2009/04/24)
Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 is structure (a), (b), (c) or (d): and Ra, Rb, Rc, R2, R3, R4, R5, R6 and R7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.